-
About Us
About Us
The word “Amicogen” consists of the meaning of friend, “AMICO”
in Latin and of gene, “GENE”. We developed innovative biocatalysts
and proteins by applying our proprietary i DNA Evolution™ Technology.
We are a “Bioengineering company just like a Sincere Friend”
who contributes to the human health and the preservation of environment.
Amicogen is the representative Industrial Biotechnology Company in Korea
and wants to contribute to the protection of human health and the environment. -
R&D
R&D
Amicogen Biotech R&D Center is expanding its R&D field based on
bio-platform technology, and researchers account for 30% of all employees.
We will lead the Industrial Biotechnology to develop new technologies
that can drive the development of humanity and society,
one step further than others.
Amicogen continues innovative research
and development for its first and best products. -
Products
Products
Amicogen has developed Special Enzymes for industrial and pharmaceutical products based on the i DNA evolution™.
We want to contribute to the sustainable growth and lifelong health
of humanity by developing New Bio-Ingredientfor Health functional foods
with Special Enzymes and Protein Purification Resin.
Amicogen develops Bio Products and
New Bio-Ingredients for Health functional food. -
Investors
Investors
As Amicogen started as a bio-venture company, we have focused on
the core competence of R&D and are pursuing sustainable growth
in innovative technologies and products. To increase the value
of enterprise and shareholder, we are continually strengthening our core competencies such as specialty enzyme business, healthcare, protein
purification resin business and others.
Amicogen strengthens key capacities
to increase enterprise value and shareholder value. -
Media
Media
Amicogen promotes various activities to realize the value of contributing
to the protection of human health and the environment.
Amicogen is positioning itself as a global biotechnology company
through growth and leaps to create new values.
You can find various looks and news of Amicogen
taking the initiative in the global bio industry. -
ESG
Sustainable management
Amicogen has developed bio innovative technologies and operated the businesses that consider humankind and environment from the perspective of sustainability for the past 20 years. We will continue sustainable development based on Amicogen's environmental soundness, social responsibility and sustainable innovative technology.
Amicogen wants to contribute to the protection of human health and the environment. -
Careers
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.
We are waiting for Amicogen people,
who will open new values and a bright future. -
CONTACT
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.We are waiting for Amicogen people,
who will open new values and a bright future.
Family Company
Family Company
Amicogen strategically invests in specialized Bio, Healthcare and precision pharmaceutical
companies to expand its business and generate future growth momentum.
| No. | Contents | |
|---|---|---|
| 1 |  |
INTHERA
InThera is a biotechnology company specializing in vaccine development based on VLP platform technology, which is promoting the development of norovirus and rotavirus vaccines. It provides Amicogen’s CMO services for InThera to develop new vaccines based on microorganisms & cell cultures and cooperate in the business. |
| 2 |  |
Lysando AG
Lysando AG, a company existing at Lichtenstein, Germany, has developed and researched the Endolysin-based drug ARTILYSIN with Amicogen over several years, and the company also has a strategic partnership with Amicogen by sharing stocks and transferring technologies.
|
| 3 |  |
ROPHIBIO
ROPHIBIO develops biologics such as antibody/protein drug, genetic/cell drug, and stem cell drug on which the genetic and cell platform is technology-based. In 2023, it is going to enter the global Phase 3 clinical trial of a biosimilar of Eylea for macular degeneration. ROPHIBIO’s biosimilar development (antibody-drug and protein drug) business and Amicogen’s biologics material (medium and resin CDMO) business soon will have a great synergetic effect.
|
| 4 |  |
BeyondCell
BeyondCell, established for developing a biologics raw medium, obtained a cell line platform development technology and the original technology by transferring technologies and establishing a Joint Venture company with ArtiaBio in the U.S.A. |
| 5 |  |
PURIOGEN
PURIOGEN is the sole producer of purified resin (Agarose bead for protein purification) for biologics raw material established for the localization plan for the resin in South Korea. The company owns producing lines for Affinity chromatography resin and IEX chromatography resin. |
| 6 |  |
Pearlzyme
It is a company developing, applying and commercializing proteins and enzymes derived from marine organisms. Pearlzyme's extreme enzyme (Patent No. 465852) possesses strong anti-inflammatory action and super-strong protein decomposition ability. We aim to commercialize a comprehensive enzyme formulation for feed additives for pigs, a compound enzyme formulation for feed additives for broilers, and an enzyme formulation for feed additives to prevent cow's breast infection. |
| 7 |  |
Amicogen (China) Biofarm Limited Company
It is a subsidiary of Amicogen, located in Shandong Province, China, and is developing and selling animal/human pharmaceutical raw materials and intermediates, as well as resins and enzymatic fixation walls for separation. A company specialized in medical raw materials (certified by Shandong Province's Excellent Technology Company), it has a production facility based on European COS and US FDA.
|